Latest News

Alzheimer's Disease Research

The Alzheimer’s risk gene APOE4 puts women at greater risk for Alzheimer’s disease than men. New research suggests this may be caused by an interaction between blood and brain immune cells that appears before any cognitive symptoms.

Aug 29, 2024
National Glaucoma Research

Driven by a desire to make a meaningful impact on public health, National Glaucoma Research grant recipient Dr. Bingrui Wang is developing glaucoma prediction technology and tools for early detection.

Aug 20, 2024
Macular Degeneration Research

BrightFocus Foundation Macular Degeneration Research grant recipient Maximilian Pfau, MD, aims to bridge this gap in available testing for AMD and detect the condition as early as possible. Learn more about his Macular Degeneration Research-funded project.

Aug 20, 2024
National Glaucoma Research

In This Issue: 

  • FDA Approves First-of-its-Kind Glaucoma Treatment
  • President’s Corner 
  • AI Identifies New Genetic Targets for Glaucoma Treatment
  • Six Common Glaucoma Eye Tests
  • And more!
Aug 6, 2024
Alzheimer's Disease Research

Alzheimer’s Disease Research, a BrightFocus Foundation program, was on the ground at the 2024 Alzheimer’s Association International Conference (AAIC) in Philadelphia to share insights on the latest research and foster scientific collaboration. Catch up on a few of the top headlines from AAIC.

Jul 31, 2024
National Glaucoma Research

In glaucoma, problems with mitochondria—a source of cell energy—can damage neurons that carry visual information from the eyes to the brain. Adriana Di Polo, PhD, is testing small molecule drugs that may prevent this damage and boost energy production in these neurons.

Jul 18, 2024
Alzheimer's Disease Research

A new BrightFocus-funded study of cognitively healthy 100-year-olds sheds light on genetic characteristics that protect the brain.

Jul 18, 2024
Macular Degeneration Research

Increased eye inflammation with age may contribute to macular degeneration and present differently between sexes, suggests a new BrightFocus-funded study.

Jul 17, 2024
Alzheimer's Disease Research

Another disease-modifying Alzheimer's therapy hits the market.

Jul 2, 2024
Alzheimer's Disease Research

On June 10, the Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee unanimously voted that Eli Lilly’s Alzheimer’s drug, donanemab, is effective for treating early symptomatic Alzheimer’s disease.

Jun 18, 2024